# A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors

> **NCT03457532** · PHASE1 · COMPLETED · sponsor: **Haihe Biopharma Co., Ltd.** · enrollment: 177 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Gumarontinib Tablets

## Key facts

- **NCT ID:** NCT03457532
- **Lead sponsor:** Haihe Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-16
- **Primary completion:** 2023-09-22
- **Final completion:** 2023-09-22
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03457532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03457532, "A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03457532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*